NASDAQ:MRTX - Mirati Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $39.74 -0.64 (-1.58 %) (As of 12/18/2018 07:56 AM ET)Previous Close$40.38Today's Range$39.53 - $43.2152-Week Range$16.16 - $65.35Volume627,909 shsAverage Volume374,655 shsMarket Capitalization$1.31 billionP/E Ratio-14.29Dividend YieldN/ABeta1.87 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Mirati Therapeutics, Inc., a clinical-stage oncology company, develops targeted therapeutics to address the genetic, epigenetic, and immunological promoters of cancer. The company is involved in developing sitravatinib, an oral spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of solid tumor; and in Phase Ib clinical trial to treat non-small cell lung cancer (NCSLC) patients with CBL, chromosome 4q12, and RET genetic alterations, as well as mocetinostat, an orally administered spectrum-selective Class 1 histone deacetylase inhibitor that is in Phase II clinical trial in combination with durvalumab for the treatment of patients with NSCLC. Its preclinical development stage product candidate include KRAS G12C inhibitor program to address mutations and tumors. The company has a collaboration and license agreement with BeiGene, Ltd. to develop manufacture and commercialize sitravatinib. It also has collaboration with Astex Pharmaceuticals, Inc. and Merck & Co., Inc.; and Array BioPharma, Inc. to develop and commercialize products. Mirati Therapeutics, Inc. is headquartered in San Diego, California. Receive MRTX News and Ratings via Email Sign-up to receive the latest news and ratings for MRTX and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:MRTX Previous Symbol CUSIPN/A Webwww.mirati.com Phone858-332-3410 Debt Debt-to-Equity RatioN/A Current Ratio11.22 Quick Ratio11.22 Price-To-Earnings Trailing P/E Ratio-14.29 Forward P/E Ratio-12.74 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.31 per share Price / Book7.48 Profitability EPS (Most Recent Fiscal Year)($2.78) Net Income$-70,420,000.00 Net MarginsN/A Return on Equity-46.80% Return on Assets-42.71% Miscellaneous Employees51 Outstanding Shares32,520,000Market Cap$1.31 billion OptionableOptionable Mirati Therapeutics (NASDAQ:MRTX) Frequently Asked Questions What is Mirati Therapeutics' stock symbol? Mirati Therapeutics trades on the NASDAQ under the ticker symbol "MRTX." How were Mirati Therapeutics' earnings last quarter? Mirati Therapeutics Inc (NASDAQ:MRTX) posted its earnings results on Tuesday, November, 6th. The biotechnology company reported ($0.85) earnings per share for the quarter, beating analysts' consensus estimates of ($0.87) by $0.02. View Mirati Therapeutics' Earnings History. When is Mirati Therapeutics' next earnings date? Mirati Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, March 14th 2019. View Earnings Estimates for Mirati Therapeutics. What price target have analysts set for MRTX? 9 Wall Street analysts have issued twelve-month price targets for Mirati Therapeutics' shares. Their predictions range from $37.00 to $65.00. On average, they expect Mirati Therapeutics' stock price to reach $55.2857 in the next year. This suggests a possible upside of 39.1% from the stock's current price. View Analyst Price Targets for Mirati Therapeutics. What is the consensus analysts' recommendation for Mirati Therapeutics? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mirati Therapeutics in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Mirati Therapeutics. What are Wall Street analysts saying about Mirati Therapeutics stock? Here are some recent quotes from research analysts about Mirati Therapeutics stock: 1. HC Wainwright analysts commented, "We derive our $65 price target from a sum-of-the-parts analysis based on probability-adjusted revenue forecasts for sitravatinib and mocetinostat. We use the net present value of our revenue forecast through 2027, apply a 50% probability of success (POS) for sitravatinib in combination with checkpoint inhibitors, a 45% POS for sitravatinib monotherapy, 15% POS for mocetinostat, our YE2018 fully diluted net cash estimate of $4.79/share, and we value the early stage pipeline at $5.38/ share to arrive at our price target. We assume a 20% discount rate for the NPV of the pipeline and a P/S multiple of 4x." (11/12/2018) 2. According to Zacks Investment Research, "Mirati Therapeutics, Inc. is a biopharmaceutical company. It engaged in the development of novel therapeutics for the treatment of cancer. Mirati Therapeutics, Inc., formerly known as MethylGene Inc., is based in Montreal, Canada. " (10/4/2018) Has Mirati Therapeutics been receiving favorable news coverage? News stories about MRTX stock have been trending negative this week, InfoTrie reports. InfoTrie scores the sentiment of media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Mirati Therapeutics earned a media sentiment score of -2.4 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 5.0 out of 10, indicating that recent media coverage is somewhat likely to have an effect on the stock's share price in the next few days. Who are some of Mirati Therapeutics' key competitors? Some companies that are related to Mirati Therapeutics include Amarin (AMRN), Alkermes (ALKS), Catalent (CTLT), Amneal Pharmaceuticals (AMRX), SAGE Therapeutics (SAGE), United Therapeutics (UTHR), HUTCHISON CHINA/S (HCM), Loxo Oncology (LOXO), TESARO (TSRO), GW Pharmaceuticals PLC- (GWPH), Taro Pharmaceutical Industries (TARO), Array Biopharma (ARRY), FibroGen (FGEN), Horizon Pharma (HZNP) and Intercept Pharmaceuticals (ICPT). Who are Mirati Therapeutics' key executives? Mirati Therapeutics' management team includes the folowing people: Dr. Rodney W. Lappe, Exec. Chairman (Age 63)Dr. Charles M. Baum, Pres, CEO & Director (Age 60)Dr. James Christensen, Chief Scientific Officer (Age 50)Dr. Isan Chen, Exec. VP and Chief Medical & Devel. Officer (Age 56)Mr. Jamie A. Donadio, Sr. VP & CFO (Age 43) Who are Mirati Therapeutics' major shareholders? Mirati Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include FMR LLC (6.59%), BlackRock Inc. (4.88%), Vanguard Group Inc. (4.40%), Vanguard Group Inc (4.40%), Janus Henderson Group PLC (3.17%) and Jennison Associates LLC (3.09%). Company insiders that own Mirati Therapeutics stock include Boxer Capital, Llc, Charles M Baum, Jamie A Donadio, Jamie Christensen, Ltd Braslyn, Tuesday Thirteen Inc and Venbio Select Advisor Llc. View Institutional Ownership Trends for Mirati Therapeutics. Which institutional investors are selling Mirati Therapeutics stock? MRTX stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace North America L.P., EAM Investors LLC, Royce & Associates LP, Dimensional Fund Advisors LP, Chicago Equity Partners LLC, Virtus ETF Advisers LLC, PNC Financial Services Group Inc. and EAM Global Investors LLC. Company insiders that have sold Mirati Therapeutics company stock in the last year include Charles M Baum, Jamie A Donadio and Jamie Christensen. View Insider Buying and Selling for Mirati Therapeutics. Which institutional investors are buying Mirati Therapeutics stock? MRTX stock was acquired by a variety of institutional investors in the last quarter, including Credit Suisse AG, Jennison Associates LLC, Janus Henderson Group PLC, Wells Fargo & Company MN, PointState Capital LP, Pictet Asset Management Ltd., FMR LLC and BlackRock Inc.. Company insiders that have bought Mirati Therapeutics stock in the last two years include Boxer Capital, Llc, Ltd Braslyn and Venbio Select Advisor Llc. View Insider Buying and Selling for Mirati Therapeutics. How do I buy shares of Mirati Therapeutics? Shares of MRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Mirati Therapeutics' stock price today? One share of MRTX stock can currently be purchased for approximately $39.74. How big of a company is Mirati Therapeutics? Mirati Therapeutics has a market capitalization of $1.31 billion. The biotechnology company earns $-70,420,000.00 in net income (profit) each year or ($2.78) on an earnings per share basis. Mirati Therapeutics employs 51 workers across the globe. What is Mirati Therapeutics' official website? The official website for Mirati Therapeutics is http://www.mirati.com. How can I contact Mirati Therapeutics? Mirati Therapeutics' mailing address is 9393 TOWNE CENTRE DRIVE SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-332-3410 or via email at [email protected] MarketBeat Community Rating for Mirati Therapeutics (NASDAQ MRTX)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 303 (Vote Outperform)Underperform Votes: 213 (Vote Underperform)Total Votes: 516MarketBeat's community ratings are surveys of what our community members think about Mirati Therapeutics and other stocks. Vote "Outperform" if you believe MRTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MRTX will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/18/2018 by MarketBeat.com StaffFeatured Article: What are retained earnings?